| TABLE OF CONTENTS | |||||||||||||||||||||||||||||||||||||
| April 2015 Volume 11 Number 4 | |||||||||||||||||||||||||||||||||||||
In this issue
| |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| NEWS AND VIEWS | Top | ||||||||||||||||||||||||||||||||||||
| Stroke: Stroke outcomes after 90 days—out of sight, out of mind? Mary Joan MacLeod & Melanie Turner Published online: 10 March 2015 p187 | doi:10.1038/nrneurol.2015.28 A recent study has found that one in six people who are independent at 3 months after stroke deteriorate and need assistance by 12 months. Older women with comorbidities, and patients not given appropriate secondary stroke prevention were most at risk. Anticipation and prevention of deterioration could help reduce the later burden of stroke. Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| Movement disorders: Friedreich ataxia today—preparing for the final battle Giuseppe De Michele & Alessandro Filla Published online: 10 March 2015 p188 | doi:10.1038/nrneurol.2015.33 Research into Friedreich ataxia has been hampered by low availability of study participants. Now, a European consortium has released baseline data from a continuing study of 592 patients with Friedreich ataxia, providing information on clinical features and progression. Such large cooperative studies might herald the final battle against this disabling disease. Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| Dementia: Cognitive resilience in APOE *Є4 carriers—is race important? Lisa L. Barnes & David A. Bennett Published online: 24 March 2015 p190 | doi:10.1038/nrneurol.2015.38 The apolipoprotein E Є4 (APOE *Є4) allele is a well-established risk factor for cognitive decline, particularly among white individuals. A recent study highlights factors associated with cognitive resilience in both black and white APOE *Є4 carriers. Despite racial differences in the frequency and impact of APOE *Є4, resilience factors are similar across races. Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| REVIEWS | Top | ||||||||||||||||||||||||||||||||||||
| The role of inflammation in perinatal brain injury Henrik Hagberg, Carina Mallard, Donna M. Ferriero, Susan J. Vannucci, Steven W. Levison, Zinaida S. Vexler & Pierre Gressens Published online: 17 February 2015 p192 | doi:10.1038/nrneurol.2015.13 Neuroinflammation during critical phases of brain development can increase the risk of neurological and neuropsychiatric disorders, even in adulthood. In this Review, Hagberg et al. review the mechanisms through which inflammation can exacerbate perinatal brain injury, and outline how understanding the interplay between inflammation and brain injury can aid the identification of new strategies to alleviate neurological and neuropsychiatric morbidity. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| Pharmacological treatment of migraine during pregnancy and breastfeeding Siri Amundsen, Hedvig Nordeng, KateÅ™ina Nezvalová-Henriksen, Lars Jacob Stovner & Olav Spigset Published online: 17 March 2015 p209 | doi:10.1038/nrneurol.2015.29 Migraine affects up to 25% of women of reproductive age. Suboptimally treated migraine during pregnancy can negatively affect both mother and fetus, but few data exist on the safety of many commonly used pharmacotherapies for migraine. This Review summarizes current evidence on the safety of the most common antimigraine drugs during pregnancy and breastfeeding, and provides treatment recommendations for clinical practice. Abstract | Full Text | PDF | Supplementary information | |||||||||||||||||||||||||||||||||||||
| Statins, cognition, and dementia—systematic review and methodological commentary Melinda C. Power, Jennifer Weuve, A. Richey Sharrett, Deborah Blacker & Rebecca F. Gottesman Published online: 24 March 2015 p220 | doi:10.1038/nrneurol.2015.35 The effects of statin treatment on the development of cognitive impairment, dementia and Alzheimer disease are unclear. In this Review, the authors systematically evaluate the findings from randomized controlled trials and observational studies that have investigated the association of statin use with cognition—including consideration of probable sources of bias—so as to summarize the current evidence and make recommendations for future work. Abstract | Full Text | PDF | Supplementary information | |||||||||||||||||||||||||||||||||||||
| CONSENSUS STATEMENT | Top | ||||||||||||||||||||||||||||||||||||
| Expert consensus document: Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions Aaron J. Carman, Rennie Ferguson, Robert Cantu, R. Dawn Comstock, Penny A. Dacks, Steven T. DeKosky, Sam Gandy, James Gilbert, Chad Gilliland, Gerard Gioia, Christopher Giza, Michael Greicius, Brian Hainline, Ronald L. Hayes, James Hendrix, Barry Jordan, James Kovach, Rachel F. Lane, Rebekah Mannix, Thomas Murray, Tad Seifert, Diana W. Shineman, Eric Warren, Elisabeth Wilde, Huntington Willard & Howard M. Fillit Published online: 17 March 2015 p230 | doi:10.1038/nrneurol.2015.30 Sports-related concussion is increasingly recognized as a potential danger to paediatric populations, but its short-term and long-term consequences remain poorly understood. This Expert Consensus Document is the result of a 1-day meeting convened by Safe Kids Worldwide, the Alzheimer's Drug Discovery Foundation, and the Andrews Institute for Orthopaedics and Sports Medicine, with the aim of highlighting knowledge gaps and areas of critically needed research in youth sports-related concussion. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| *Journal Citation Reports, Thomson, 2013. Nature Reviews Neurology was previously published as Nature Clinical Practice Neurology. |
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. |
No comments:
Post a Comment
Keep a civil tongue.